Attendee search 

Metanomics Health, a BASF group company, is the world leading company offering targeted and non-targeted metabolite profiling to healthcare customers in industry and academia. We serve pharma, nutrition and diagnostics customers, making them more successful through biomarker identification and validation across a broad range of applications.

In parallel to our third party service business we are funding and conducting a comprehensive diagnostic biomarker program in the areas of cardio-metabolic diseases, multiple sclerosis and various oncology indications, addressing open questions of high and unmet medical need.

Biomarkers covering disease diagnosis, mechanism of drug toxicity, mechanism of action and drug efficacy are increasingly needed in the preclinical and clinical setting for better evaluation of novel chemical entities including target validation and tailor-made treatment regimens.

Our non-biased broad profiling platform as well as the hypothesis-driven targeted metabolomics platforms have the potential for providing novel biomarkers of disease and drug efficacy and are routinely incorporated into biomarker discovery and validation studies.

We enhance contextualization of our reproducible and robust metabolic signatures via integration with data from other “-omics” platforms such as transcriptomics or proteomics. In our systems biology approach we are linking known metabolites and genes to relevant pathways and phenotypes, i.e. mapping genotype to phenotype.

Our customers´ personalized medicines and nutrition solutions are guided by differentiated and robust metabolite biomarker signatures, thus making sure that the right intervention is selected for the right person at the right time.

Sorrento Therapeutics, Inc. is a development-stage biopharmaceutical company focused on applying its proprietary technology platform for the discovery and development of human therapeutic antibodies for the treatment of a variety of disease conditions, including cancer, inflammation, metabolic disease and infectious disease. The Company has constructed antibody libraries containing fully human antibodies and designed to facilitate the rapid identification and isolation of highly specific, antibody therapeutic product candidates that are fully human and that bind to disease targets.

The Ono Pharmaceutical Group, in keeping with our philosophy of "Dedicated to Man's Fight against Disease and Pain," has always striven to serve as an R&D-oriented international pharmaceutical company.  In this endeavor we have placed our emphasis on creating innovative medicines that meet international requirements.  In addition to its own original research and development efforts, Ono has been very activly seeking a in-licensing opportunity from companies inside and outside Japan.

Karolinska Development aims to create value for investors, patients, and researchers by developing innovations from world class science into products that can be sold or out-licensed with high returns. The business model is to: SELECT the most commercially attractive medical innovations; DEVELOP innovations to the stage where the greatest return on investment can be achieved; and COMMERCIALIZE the innovations through the sale of companies or out-licensing of products.

Today, the portfolio consists of 35 projects, of which 14 are pharmaceuticals in clinical development, 7 in phase I and 7 in phase II

In the active portfolio, Karolinska Development has four projects in oncology, whereof three in clinical development, four clinical development programs in skin disease and wound healing, three projects in women’s health, two in infection, two in CVD, CNS and inflammation respectively and one in opthalmology. Furthermore, 10 technology programs in the areas of implants, diagnostics, formulation and medical equipment. Several are open for licensing and co-development discussions.

We are also looking for breakthrough investment opportunities in the areas of Life Sciences (pharma/biotech, medtech)

Kowa Company, Ltd is a privately-held Japanese corporation headquartered in Nagoya. Since its establishment as a textile wholesaler in 1894, Kowa has grown into a multinational company with 48 affiliates around the world and has built a strong position in developing, manufacturing, marketing and trading products within a variety of businesses. Kowa started its pharmaceutical business in 1947, and has since built a strong presence in the Japanese prescription and OTC drug markets and it is growing rapidly overseas.

Areas of Interest

•      Cardiovascular

•      Metabolic Syndromes

•      Pain Management

•      Auto-inflammatory

•      Gastroenterological

Partnership Structures

•      Co-development

•      Co-commercialization

•      Licensing

•      Across all stages of development & commercialization